

## **Wastewater monitoring outperforms case numbers as a tool to track COVID-19 incidence dynamics when test positivity rates are high**

Xavier Fernandez-Cassi<sup>1</sup>, Andreas Scheidegger<sup>2</sup>, Carola Bänziger<sup>2</sup>, Federica Cariti<sup>1</sup>, Alex Tuñas Corzon<sup>1</sup>, Pravin Ganesanandamoorthy<sup>2</sup>, Joseph C. Lemaitre<sup>3</sup>, Christoph Ort<sup>2</sup>, Timothy R. Julian<sup>2,4,5</sup>, Tamar Kohn<sup>1\*</sup>

<sup>1</sup> Laboratory of Environmental Chemistry, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

<sup>2</sup> Swiss Federal Institute of Aquatic Science and Technology (Eawag), 8600 Dübendorf, Switzerland

<sup>3</sup> Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

<sup>4</sup> Swiss Tropical and Public Health Institute, CH-4051 Basel, Switzerland

<sup>5</sup> University of Basel, CH-4055 Basel, Switzerland

\* To whom correspondence should be addressed: e-mail: [tamar.kohn@epfl.ch](mailto:tamar.kohn@epfl.ch); phone: +41 21 69 30891.

1 **Abstract**

2 Wastewater-based epidemiology (WBE) has been shown to coincide with, or anticipate, confirmed COVID-  
3 19 case numbers. During periods with high test positivity rates, however, case numbers may be  
4 underreported, whereas wastewater does not suffer from this limitation. Here we investigated how the  
5 dynamics of new COVID-19 infections estimated based on wastewater monitoring or confirmed cases  
6 compare to true COVID-19 incidence dynamics. We focused on the first pandemic wave in Switzerland  
7 (February to April, 2020), when test positivity ranged up to 26%. SARS-CoV-2 RNA loads were determined  
8 2-4 times per week in three Swiss wastewater treatment plants (Lugano, Lausanne and Zurich).  
9 Wastewater and case data were combined with a shedding load distribution and an infection-to-case  
10 confirmation delay distribution, respectively, to estimate incidence dynamics. Finally, the estimates were  
11 compared to reference incidence dynamics determined by a validated compartmental model. Incidence  
12 dynamics estimated based on wastewater data were found to better track the timing and shape of the  
13 reference infection peak compared to estimates based on confirmed cases. In contrast, case  
14 confirmations provided a better estimate of the subsequent decline in infections. Under a regime of high-  
15 test positivity rates, WBE thus provides critical information that is complementary to clinical data to  
16 monitor the pandemic trajectory.

17 **Keywords**

18 Sewage, new infections, compartmental model, shedding load distribution, SARS-CoV-2, disease dynamics

## 19 **1. Introduction**

20 Wastewater-based epidemiology (WBE), a form of environmental surveillance of infectious diseases, has  
21 long been suggested as a sensitive tool to monitor pathogen circulation in a population<sup>1-3</sup>. Many  
22 pathogens, both enteric and otherwise, are excreted from infected individuals into the sewage system via  
23 feces, saliva or other bodily fluids<sup>1</sup>. The principle underlying WBE is that the pathogen concentrations or  
24 loads in sewage are proportional to the number of infected individuals among the population contributing  
25 to the sewage, and can thus inform on the presence and trajectory of a disease outbreak. For example,  
26 norovirus concentrations in sewage were found to closely track the dynamics gastroenteritis cases over  
27 several years in Japan<sup>4</sup>. WBE can inform not only on the presence and dynamics of a pathogen but may  
28 also capture the emergence of new strains or variants before they become widespread in a population<sup>4,5</sup>.

29 WBE has received renewed attention during the COVID-19 pandemic, when it was recognized that SARS-  
30 CoV-2 RNA is excreted in feces<sup>6</sup> and can be detected in wastewater<sup>7-9</sup> and sludge<sup>10,11</sup>. Several studies have  
31 shown that the dynamics of SARS-CoV-2 RNA in raw wastewater or sludge coincide with, or even  
32 anticipate, the dynamics of confirmed cases<sup>7,10,11</sup>. In addition, WBE was able to capture the introduction  
33 and spread of SARS-CoV-2 variants of concern<sup>12</sup>, and identify mutations that were not captured in clinical  
34 samples<sup>13</sup>. WBE may thus serve as a useful tool to support COVID-19 monitoring, and WBE data have  
35 already been integrated into multiple national or local COVID-19 dashboards<sup>14-17</sup>.

36 While WBE will never replace case reporting, it can be used to strengthen the understanding of infectious  
37 disease dynamics as it holds important benefits over clinical tests. Specifically, WBE captures both  
38 symptomatic and asymptomatic virus shedders; WBE data are not affected by testing capacity, strategy  
39 or compliance; and WBE allows the monitoring of a large population with few samples. The advantages  
40 of WBE over clinical testing are particularly important when test capacity is exceeded and hence may be  
41 insufficient to accurately capture case numbers. According to the WHO, the test positivity rate should

42 remain < 5% to confidently track disease dynamics<sup>18</sup>. Under regimes with a positivity rate > 5%, WBE may  
43 thus better reflect true disease dynamics than clinical case numbers.

44 In this study we evaluated the use of wastewater monitoring as a tool to track COVID-19 dynamics. We  
45 hypothesized that under high test positivity rates, wastewater provides an improved estimate of the  
46 dynamics of new infections (incidence dynamics) compared to confirmed case numbers. We focused on  
47 the first wave of the COVID-19 pandemic in Switzerland, which lasted from late February to April 2020.  
48 The test positivity rate during this period ranged up to 26 % (Figure S1). Wastewater was monitored 2-4  
49 times per week in two locations (Lugano, Lausanne) that were strongly affected, and one location (Zurich)  
50 that experienced a milder wave. We did not directly evaluate SARS-CoV-2 RNA loads measured in  
51 wastewater against the number of confirmed cases. Instead, we use these metrics to estimate the  
52 incidence dynamics over time. This allowed us to compare both the wastewater- and the case number-  
53 derived incidence dynamics to reference incidence dynamics determined retrospectively by a  
54 compartmental (Susceptible-Exposed-Infected-Recovered; SEIR) model and consistent with  
55 seroprevalence studies conducted in the region<sup>19</sup>.

## 56 **2. Materials and Methods**

### 57 ***2.1. Experimental approach***

58 We determined the concentration and daily loads of SARS-CoV-2 RNA in longitudinal samples of raw  
59 wastewater collected from three Swiss wastewater treatment plants (WWTPs). In each sample, we  
60 analyzed two SARS-CoV-2 gene targets (N1 and N2). In addition, we determined virus recovery by means  
61 of an externally added viral surrogate of SARS-CoV-2. Finally, we monitored the fecal strength in each  
62 sample via the analysis of pepper mild mottle virus (PMMoV), a plant virus that occurs in wastewater at  
63 high and constant concentrations<sup>20,21</sup>.

64 **2.2. Sample collection and storage**

65 24-h composite influent samples were collected 2-4 times per week between February 26 and April 30,  
66 2020 from three Swiss WWTPs: Lausanne (STEP de Vidy; population connected: 240'000; 25 samples),  
67 Lugano (CDA Bioggio; population connected: 125'000; 31 samples); and Zürich (ARA Werdhölzli:  
68 population connected: 450'000; 22 samples). After collection, the wastewater samples were stored at -  
69 20 °C for up to 5 months.

70 **2.3. Preparation of viral surrogate stock solutions**

71 Three enveloped viruses were assessed as external recovery controls, namely Murine Hepatitis Virus  
72 (MHV, *Coronaviridae*, *betacoronavirus*), *Pseudomonas virus*  $\Phi 6$  (*Cystoviridae*, *cystovirus*) and Murine  
73 Sendai virus (*Paramyxoviridae*, *respirovirus*). Murine Hepatitis Virus strain MHV-A59 (kindly donated by  
74 Volker Thiel, University of Bern) was propagated in DBT cells (kindly donated by Krista Rule Wigginton,  
75 University of Michigan) as described elsewhere<sup>22</sup>. Five days post-infection the viral particles were released  
76 from infected cells by three cycles of freezing/thawing. Cell supernatants were centrifuged at 3000  $xg$  to  
77 pellet down cell debris and the supernatant was clarified through a 0.22  $\mu m$  filter. The resulting stock  
78 solution had a concentration of  $7.8 \times 10^9$  genome copies (gc)/ml. Bacteriophage  $\Phi 6$  (DSMZ n° 21518, strain  
79 HER 102) was propagated in *P. syringae* (DSMZ n° 21482, strain HER1102) according to the provider's  
80 instructions. After propagation, bacterial cultures were centrifuged at 8000  $xg$  for 10 min and cell debris  
81 was removed by passing the supernatant through a 0.22  $\mu m$  filter. The final stock solution had a  
82 concentration of  $8.0 \times 10^8$  gc/ml. Finally, Sendai virus propagated in embryonated eggs was kindly donated  
83 by Dominique Garcin (University of Geneva) and was used without further treatment. These solutions had  
84 a concentration of  $1.3 \times 10^9$  gc/ml.

85

#### 86 **2.4. Sample concentration and nucleic acid extraction**

87 Samples from Lugano and Lausanne were processed at EPFL, and samples from Zürich were processed at  
88 Eawag. Prior to processing, samples were thawed at room temperature. For each sample, two replicate  
89 aliquots of 50 ml wastewater were processed. The 50 ml aliquots were spiked with MHV (Lausanne or  
90 Lugano) or Sendai virus (Zürich) at a concentration of approximately  $1 \times 10^6$  gc/50 ml, and were stirred for  
91 20 minutes to ensure the homogenization of the sample. Then they were pre-filtered using 2  $\mu$ m glass  
92 fiber pre-filters (Merck, cat n° AP2007500) placed on the top of 0.22  $\mu$ m SteriCup filters (Merck, cat n°  
93 SCGVU02RE). After filtration, the filter units were rinsed with 10 ml of ultrapure water to ensure that no  
94 wastewater was retained in the dead volume. The filtrates (approximately 60 ml) were transferred to a  
95 centrifugal filter unit with a size cut-off of 100 kDa (Centricon Plus-70; Millipore cat n° UFC701008), and  
96 were centrifuged for 30 min at 3000xg. To collect the concentrate, the centrifugal filter was inverted and  
97 centrifuged for 3 min at 1000xg. The resulting viral concentrate volume ranged from 180 to 300  $\mu$ L.

98 Viral concentrates were extracted in their entirety using the Qiagen RNA Viral Mini Kit (Qiagen cat n°  
99 22906, Valencia, CA, USA) following the manufacturer's protocol for higher volumes. Nucleic acids were  
100 eluted using 80  $\mu$ l of AVE buffer. For each processed batch of samples, a negative extraction control using  
101 water was included. The extracted nucleic acids were passed through a Zymo OneStep PCR Inhibitor  
102 Removal column (Zymo Research, cat n° D6030) to remove PCR inhibitors following the protocol provided  
103 by the manufacturer.

104 In addition to the longitudinal samples, seven wastewater samples were collected in Lausanne to test the  
105 recovery of different SARS-CoV-2 surrogates. These samples were spiked with MHV, Sendai virus and  $\Phi$ 6  
106 at a concentration of approximately  $10^6$  gc/50 ml each. Samples were then concentrated and nucleic acids  
107 were extracted as described above.

108 **2.5. Quantification of SARS-CoV-2 N1 and N2 genes, viral surrogates and PMMoV by RT-qPCR**

109 All RNA extracts of the longitudinal samples were analyzed by RT-qPCR for four viral targets: The N1 and  
110 N2 genes of SARS-CoV-2, the surrogate virus and PMMoV. All N1, N2 and MHV analyses, as well as PMMoV  
111 analyses for Lugano and Lausanne were performed at EPFL. PMMoV and Sendai virus analyses for Zürich  
112 were performed at Eawag. The samples to test surrogate virus recovery were analyzed at EPFL for three  
113 viral targets: MHV, Sendai virus and  $\Phi 6$ . To detect the presence of SARS-CoV-2 RNA, the CDC N1 and N2  
114 assays were used<sup>23</sup>. PMMoV and MHV were analyzed by previously reported assays<sup>24-26</sup>. The design for  
115 primers and probes for  $\Phi 6$  were adapted from Gendron et al<sup>27</sup> according to the suggestion of Heather  
116 Bischel (University of California, Davis). For Sendai virus, primers and probes were designed for the  
117 purpose of this project. A summary of all primers and probes and the RT-qPCR protocols is given in the  
118 Supporting Information (Table S1).

119 To calibrate the different RT-qPCR assays, standard curves for each viral target were generated using  
120 either double-stranded DNA gblocks gene fragments (viral surrogates and PMMoV), or a 2019-nCoV\_N  
121 positive control plasmid (cat n° 10006625, SARS-CoV-2 N1 and N2). Both gBlocks and plasmids were  
122 purchased from Integrated DNA Technologies (Coralville, IA, USA).

123 RT-qPCR amplifications were performed in 25  $\mu$ l reactions using RNA UltraSense™ One-Step Quantitative  
124 RT-PCR System (Invitrogen, cat n° 11732-927), amended with 4  $\mu$ l of bovine serum albumin (2 mg/ml) on  
125 a Mic qPCR Cycler (Bio Molecular Systems). In each RT-qPCR reaction, 5  $\mu$ l of RNA extract or calibration  
126 standard were used. For PMMoV, the RNA extract was diluted 1:10 prior to RT-qPCR analysis. All RT-qPCR  
127 runs included no-template controls and negative extraction controls to monitor for contamination during  
128 the extraction and amplification process. The preparation of PCR mastermix and standards, as well as  
129 sample loading were performed in separate locations to avoid contamination. Cq determination was  
130 performed using the micPCR software (v2; Bio Molecular Systems).

131 RT-qPCR limits of detection (LOD) were determined as the lowest concentration (N1, N2 and MHV) or the  
132 lowest standard (PMMoV, Sendai, Φ6) with a 95% or greater detection probability. The limit of detection  
133 (LOD) for each gene target were determined from pooled standard curves ( $n \geq 3$ ) in R using the Generic  
134 qPCR Limit of Detection (LOD) / Limit of Quantification (LOQ) calculator<sup>28</sup>. Samples with a measurable RT-  
135 qPCR signal < LOD were assigned the concentration of the LOD of the respective assay. Samples which  
136 yielded no detectable RT-qPCR signal were set to the theoretical minimal LOD (3 gc/reaction)<sup>29</sup>.

## 137 **2.6. RT-qPCR inhibition**

138 To check for inhibition during RT-qPCR reactions, 4 µl of each zymo-treated RNA extract were amended  
139 with 1 µl of a synthetic SARS-CoV-2 RNA reference material (EURM-019, Joint Research Center) at a  
140 concentration of approximately  $10^5$  gc/µL. RNA extracts were analyzed for the SARS-CoV-2 N1 target by  
141 the RT-qPCR protocol described above, and the resulting Cq values were compared between samples.  
142 Samples were considered inhibited when Cq was > 1.5 cycles beyond the average Cq measured at a given  
143 site. All inhibition tests were conducted at EPFL.

## 144 **2.7. Recovery**

145 Recovery was calculated as the ratio of surrogate virus recovered after sample processing and the virus  
146 originally spiked into 50 ml of unfiltered wastewater (equation 1):

$$147 \quad \text{Recovery} = \frac{\text{virus measured per } \mu\text{l RNA extract} \times \text{RNA extraction volume (80 } \mu\text{l)}}{\text{virus spiked into 50 ml of wastewater}} \quad (1)$$

## 148 **2.8. Determination of RNA loads**

149 Genome copies (gc) per reaction were converted to units of load (gc/day) by determining the gc  
150 concentration per liter of wastewater and multiplication by the wastewater flow rate of corresponding  
151 day according to equation 2:

$$152 \quad \text{Load (gc/day)} = \frac{C_{PCR} \times V_{\text{extract}} / V_{PCR}}{V_{\text{sample}} \times Q} \quad (2)$$

153 Where  $C_{PCR}$  is the template concentration (gc/reaction) determined by RT-qPCR,  $V_{\text{extract}}$  is the total volume  
154 of RNA extract (80  $\mu\text{L}$ ),  $V_{PCR}$  is the volume of extract analyzed by RT-qPCR (5  $\mu\text{L}$ ),  $V_{\text{sample}}$  is the volume of  
155 the wastewater sample (0.05 L), and  $Q$  is the wastewater flow rate on a given sampling day measured and  
156 provided by the WWTPs included in this study (L/day).

### 157 **2.9. Storage test**

158 To determine if storage at  $-20^\circ\text{C}$  had a detrimental effect on SARS-CoV-2 RNA concentrations in  
159 wastewater, a control experiment was conducted. A batch of wastewater influent from Lausanne was  
160 collected and stored for a month in four different conditions: 1) unprocessed wastewater at  $4^\circ\text{C}$ ; 2)  
161 unprocessed wastewater at  $-20^\circ\text{C}$ ; 3) concentrated wastewater (after filtration and ultracentrifugation)  
162 at  $-20^\circ\text{C}$ ; and 4) zymo-treated RNA extract at  $-20^\circ\text{C}$ . All tests were conducted in duplicate. After one  
163 month, all samples were fully processed and immediately analyzed for the N1 gene target by RT-qPCR as  
164 described above.

### 165 **2.10. Epidemiological data**

166 Confirmed case numbers for each WWTP catchment were kindly provided by the Swiss Federal Office of  
167 Public Health.

### 168 **2.11. Incidence estimates**

169 Reference infection numbers were determined by an SEIR model described previously<sup>19</sup>. This model is  
170 based on cantonal hospitalization data, intensive care unit visits and deaths, but not case numbers. This  
171 is to avoid any influence from changes in test strategies and test capacity over the time period considered.  
172 The modeled incidence includes both symptomatic and asymptomatic new infections. The model was

173 validated against a seroprevalence study conducted in the region, and we therefore consider it herein as  
174 the reference incidence.

175 Incidence was additionally estimated based on longitudinal data of SARS-CoV-2 loads in wastewater and  
176 based on confirmed cases. Both these metrics measured at time  $t$  reflect an aggregate of infections that  
177 occurred over a time span preceding the measurement. A deconvolution of these aggregated quantities  
178 allows for the reconstruction of daily infections. This requires an assumption of the extent by which  
179 previous infections influence the aggregated quantities. This assumption is expressed by time delay-  
180 dependent weight  $\omega(\tau)$ , where  $\tau$  is the time (days) since infection. The measured aggregated quantity  $A$   
181 at time  $t$  can be approximated by a weighted sum of all infections  $I$  that occurred up to time  $t$ :

$$182 \quad A_t \approx \sum_{\tau=0}^{\infty} \omega(\tau) I_{t-\tau} \quad (3)$$

183 The infections  $I$  over a time range of interest can be estimated via non-negative least squares regression.  
184 As fast fluctuations in the number of daily infections seems unreasonable, an additional constraint was  
185 added to enforce smoothness comparable to the infection numbers of the SEIR model (see Supporting  
186 Information).

187 To obtain the wastewater-derived incidence, the weights of the deconvolution,  $\omega(\tau)$ , are given by the  
188 shedding load profile (SLP) that describes the average amount of virus shed by a patient  $\tau$  days after  
189 infection. The SLP can be decomposed into the relative shedding load probability distribution (SLD) and  
190 the absolute viral load shed during the course of the disease ( $L$ ) (equation 4):


$$191 \quad SLP(\tau) = L \times SLD(\tau) \quad (4)$$

192 The SLD was constructed by combining the gastrointestinal viral load as a function of time after symptom  
193 onset with the time between infection and symptoms. Virus shedding was modelled based on data

194 reviewed by Benefield et al.<sup>30</sup>, and could be well described by a gamma distribution with a mean of 6.73  
195 days and a standard deviation (sd) of 6.98 days. The time between infection and symptoms was also  
196 modeled by a gamma distribution based on Linton et al.<sup>31</sup> (mean = 5.3 days, sd = 3.2 days). The convolution  
197 of these two distributions was used as the SLD (shown in Figure 1a) with a mean = 11.73 days and an sd =  
198 7.68 days.

199 If L is known with small uncertainty, the absolute number of infections can be estimated. However,  
200 although the different SLDs have a comparable shape across literature, the loads L are highly variable<sup>32,33</sup>.  
201 Therefore, we applied the SLD, which still yields an estimate that is proportional to that obtained by using  
202 the correct but unknown SLP.

203 For the case number-derived incidence, ( $\tau$ ) was defined by the distribution combining the delays from  
204 infection to symptom onset (gamma mean= 5.3 days; sd = 3.2 days), and from symptom onset to case  
205 confirmation (gamma mean= 5.5 days, sd = 3.8 days<sup>34</sup>). The resulting delay distribution from infection to  
206 case confirmation is visualized in Figure 1b.



207  
208 *Figure 1: a) Shedding load distribution to describe the relative distribution of the SARS shedding load, based on the*  
209 *delay distribution from infection to symptom onset by Linton et al.<sup>31</sup>, combined with the gastrointestinal viral load*

210 *dynamics according to Benefield et al.<sup>30</sup> b) Delay distribution from infection to symptom onset according to Linton*  
211 *et al.<sup>31</sup> (solid line), and combined with an additional delay from symptom onset to case confirmation based on Bi et*  
212 *al.<sup>34</sup> (dashed line).*

## 213 **2.12. Data analysis**

214 All statistical analyses were performed in R<sup>35</sup>. The non-negative least-square regression for the incidence  
215 estimations was implemented with the package ‘CVXR’<sup>36</sup> and delay distributions were computed with the  
216 R package ‘distr’<sup>37</sup>.

## 217 **2.13. Data availability**

218 Data will be made available on an institutional repository upon acceptance of the manuscript.

## 219 **3. Results and Discussion**

### 220 **3.1. Method performance**

221 3.1.1. PCR efficiency and LOD. PCR efficiencies for all targets ranged from 94-111% (Table S2). The R<sup>2</sup> of  
222 the pooled standard curves were  $\geq 0.95$ . No amplification signal was measured in the non-template and  
223 negative extraction controls confirming the absence of contamination during sample processing. The LOD  
224 corresponded to 4.2 gc/ml wastewater and 2.6 gc/ml wastewater for the SARS-CoV-2 N1 and N2 genes,  
225 respectively. The LODs reflect the difficulty of producing accurate calibration curves for SARS-CoV-2 in the  
226 low template range based on plasmid standards. This limitation, which was also reported by others<sup>38,39</sup>  
227 highlights the need for improved qPCR standards and more sensitive RT-qPCR assays to minimize  
228 variability and false negative results in SARS-CoV-2 RNA quantification. The LODs of the other targets are  
229 listed in Table S2.

230 3.1.2. PCR Inhibition. Spiking RNA extracts with synthetic SARS-CoV-2 RNA reference material revealed  
231 minimal PCR inhibition on most samples. Specifically, with the exception of three samples from Lugano,  
232 all spiked RNA extracts exhibited N1 Cq values that fell within or only minimally beyond 1.5 cycles of the  
233 median Cq of a given WWTP (Figure S2).

234 3.1.3. Reproducibility: We compared quantifiable N1 concentrations determined in biological as well as  
235 in technical replicate samples (Figure S3). A good correlation ( $r=0.89$ ) was obtained among biological  
236 replicates, indicating a high reproducibility of the overall processing pipeline. A good reproducibility was  
237 also found for technical replicates ( $r=0.78$ ).

238 3.1.4. Recovery. Three enveloped viruses - MHV, Sendai virus and  $\Phi 6$  - were evaluated as SARS-CoV-2  
239 surrogates to monitor virus recovery in our sample processing pipeline. As a member of the *Coronaviridae*  
240 family, MHV is the most similar to SARS-CoV-2 in terms of size (120 nm diameter) and genome structure  
241 (single-stranded RNA). Sendai virus has a single-stranded RNA genome, but is slightly larger in diameter  
242 than SARS-CoV-2 (150 nm). Besides SARS-CoV-2, this virus may also serve as a surrogate for viruses with  
243 pandemic potential in the *Paramyxoviridae* family, such as measles virus. The novel RT-qPCR assay  
244 developed herein was able to quantify its concentration down to an LOD of 4.2 gc/ml (Table S2). Finally,  
245  $\Phi 6$  is the least similar surrogate to SARS-CoV-2. It has a smaller diameter (85 nm) and a different genome  
246 structure (double-stranded RNA).


247 In seven wastewater samples spiked with all three surrogate viruses, MHV and Sendai virus exhibited  
248 similar recoveries that mostly ranged from 0.1-1% (Figure S4). This range corresponds well to that  
249 reported by other groups using a similar processing pipeline<sup>40</sup>. If determined using  $\Phi 6$ , recoveries were  
250 10- to 100-fold higher and more constant across samples. This confirms previous reports that recoveries  
251 depend strongly on the surrogate virus used<sup>40</sup>. Despite the better recovery of  $\Phi 6$ , we decided to utilize

252 MHV or Sendai virus as recovery controls in this work, due to their higher structural similarity with SARS-  
253 CoV-2.

254 The recoveries in the samples from Lugano and Lausanne were determined using MHV (Figure S5).  
255 Recoveries were similar for both sites and mostly fell into the 0.1-1% range, with average values of 0.95%  
256 and 0.74% for Lugano and Lausanne, respectively. In the samples from Zurich, Sendai virus was used as  
257 the surrogate. Compared to Lugano and Lausanne, the recoveries were significantly lower, with an  
258 average of 0.17% (one-way ANOVA,  $F=6.82$ ,  $p < 0.002$ ) (Figure S5). The lower recovery is unlikely to be a  
259 result of the use of Sendai virus, since MHV and Sendai virus yielded similar recoveries if assessed in the  
260 same sample (Figure S4). Instead, the lower recoveries in the Zurich samples may reflect the higher solids  
261 content in this WWTP. Enveloped viruses partition to wastewater solids<sup>41</sup>, and hence a higher solids  
262 content leads to a reduced recovery of the surrogate virus from the liquid wastewater fraction.

263 3.1.5. Fecal load: The daily load of PMMoV was used as an indicator of the fecal load entering the  
264 WWTP. On average, the PMMoV loads corresponded to  $8.9 \times 10^{15}$  gc/day (Lugano),  $3.1 \times 10^{16}$  gc/day  
265 (Lausanne) and  $1.8 \times 10^{16}$  gc/day (Zurich) (Figure S6). In all but five samples the PMMoV load fell within  
266 the range of  $5 \times 10^{15}$  to  $5 \times 10^{16}$  gc/day. The narrow range of the measured PMMoV loads further confirms  
267 the consistency of our virus concentration and extraction process.

268 3.1.6. Effect of storage conditions on RNA stability. As shown in Figure 2, different storage procedures  
269 exert significantly different effects on SARS-CoV-2 RNA stability (one-way ANOVA,  $F=12.8$ ,  $p < 0.001$ ).  
270 Storing raw wastewater at 4 °C or -20 °C for a month resulted in lower concentrations of SARS-CoV-2 RNA  
271 compared to samples stored as concentrates or RNA extracts at -20 °C (Tukey-Kramer,  $p < 0.02$ ). The  
272 storage protocol used herein (raw wastewater at -20 °C) had to be implemented before storage tests  
273 could be completed, and likely led to significant RNA decay. In future studies, wastewater samples should  
274 immediately be concentrated or extracted prior to storage.



275  
276 *Figure 2: Effect of sample storage over one month under different conditions on SARS-CoV-2 RNA concentrations (N1*  
277 *gene, gc/ml wastewater). Error bars represent standard deviations of replicate samples. Samples stored as non-*  
278 *processed raw wastewater (WW) at 4 °C or -20 °C exhibited lower concentrations compared to samples stored at -20*  
279 *°C as concentrate (post ultrafiltration) or RNA extracts. Indices a and b denote experimental conditions yielding*  
280 *statistically different sample means.*

### 281 **3.2. Longitudinal trends SARS-CoV-2 RNA loads and confirmed cases**

282 Concentrations of SARS-CoV-2 N1 and N2 genes in longitudinal samples are shown in Figure S7. The  
283 earliest detection of the N1 gene occurred in wastewater from Lugano on February 28 2020, four days  
284 after the first case was observed in Switzerland. This confirms earlier reports that wastewater can serve  
285 as a sensitive indicator for virus circulation, even during periods of low disease prevalence <sup>7,8,42,43</sup>.


286 N1 and N2 concentrations exhibited similar temporal trends, though N1 concentrations were on average  
287 3-fold higher (Figure S7). Higher concentrations of the N1 gene were also reported by others <sup>38,44</sup>, though  
288 some studies have reported the N2 gene to yield higher results<sup>7,45</sup>. Given the superior quantification by  
289 N1 in this work, only this gene target was considered for all subsequent analyses.

290 We did not normalize N1 concentrations by fecal strength (PMMoV concentration) as suggested  
291 elsewhere<sup>44,46</sup>, because PMMoV concentrations were similar in all samples and were not correlated with

292 N1 concentrations ( $r=0.02-0.04$ ) (Figure S8). We also did not correct N1 concentrations for recovery,  
293 because there was high inter-sample variation across the three surrogates tested, and it is uncertain which  
294 - if any - externally added surrogate accurately mimics the fate of SARS-CoV-2 during sample  
295 processing<sup>11,39</sup>. Recovery values were strictly used for data quality control. Specifically, samples were  
296 excluded if two criteria were simultaneously met: the recovery of a sample was  $> 3x$  the median recovery  
297 for the site under consideration; and the concentrations measured by N1 and N2 differed by more than a  
298 factor 5. This led to the exclusion of one biological replicate on three sampling days in Lugano (March 18-  
299 19 and April 5), and both replicates for a single day in Lausanne (March 28).

300 Among the three WWTPs studied, Lausanne had the highest number of confirmed cases in its catchment  
301 (Figure 3). Case numbers were similar in the catchments of the Lugano and Zurich WWTPs, even though  
302 Zurich's catchment encompasses approximately 3.6-fold more inhabitants than Lugano's, and 1.9-fold  
303 more than Lausanne's. Consequently, the N1 concentrations in the Zurich WWTP were expected to be  
304 lower compared to Lugano and Lausanne, as confirmed by our measurements (Figure S7). To enable a  
305 direct comparison among WWTPs, we converted N1 concentrations into units of daily N1 load (equation  
306 2). This unit accounts for differences in catchment size (via the daily wastewater flow rate), and also  
307 incorporates daily variability in the wastewater flow of a given WWTP.

308 Similar to data from other studies<sup>10,11,38</sup>, there was considerable day-to-day variability in both the N1 loads  
309 and the number of confirmed cases (Figure 3). The variability in confirmed cases is increased by the fact  
310 that Switzerland reduces testing and reporting on weekends. To facilitate the visualization of pandemic  
311 trends in wastewater and case data, we therefore calculated weekly averages (Monday - Sunday) for each  
312 data set. The corresponding results are shown as solid lines in Figure 3. As is evident, both data sets  
313 feature a prominent peak in late March. However, the wastewater peak shape is narrow, whereas the  
314 number of confirmed cases remained high for 2-3 weeks.



315  
316 *Figure 3: SARS-CoV-2 RNA (N1) loads and confirmed cases for the Lausanne, Lugano and Zurich WWTP catchments*  
317 *from February 26 until April 30, 2020. Data points represent wastewater data (average of technical replicates). Circles*  
318 *and triangles indicate biological replicates. Grey bars show confirmed cases. Lines connect weekly (Monday-Sunday)*  
319 *averages of SARS-CoV-2 RNA loads or confirmed cases.*

320 Despite the similarity in confirmed case numbers in the catchment, measured SARS-CoV-2 RNA loads were  
321 higher in the Lugano WWTP than in Zurich WWTP. There are a number of potential methodological  
322 explanations for this, including lower virus recovery in Zurich (Figure S5), lower precision in quantifying  
323 low SARS-CoV-2 RNA copy numbers (Figure S7), and our sample storage protocol, which in retrospect was

324 found to be non ideal (Figure 2). The Zurich WWTP is located in the area of lowest disease prevalence and  
325 thus had the lowest starting concentrations of SARS-CoV-2 RNA among the WWTPs sampled. Further  
326 decay during storage of the Zurich samples may have lowered the concentrations below the LOD in all but  
327 the samples taken during the peak of the first wave.

### 328 ***3.3. Comparison of incidence dynamics from wastewater data, case numbers and SEIR models***

329 To assess the ability to track disease dynamics with SARS-CoV-2 loads in wastewater and confirmed cases,  
330 both data sets were used to estimate disease incidence over time (by deconvoluting the signals, see  
331 Materials and Methods). The resulting trends were compared to the reference incidence determined by  
332 an SEIR model<sup>19</sup>. While the SEIR model reports absolute infection numbers, this determination is currently  
333 not feasible for wastewater- or case number-derived estimates. For wastewater, estimating absolute  
334 infection numbers would require a better understanding of the magnitude of the shedding load  $L$   
335 (equation 4), the decay kinetics of SARS-CoV-2 RNA in the sewer system, and the true recovery of SARS-  
336 CoV-2 in our sample processing pipeline. These parameters are currently not available, but may become  
337 better known in the future. For case numbers, the ratio of confirmed to total cases would have to be  
338 known, yet this parameter is associated with considerable uncertainty and likely variability during the first  
339 wave of the pandemic. We therefore only compared the incidence dynamics, but not the absolute  
340 incidence per day.

341 As shown in Figure 4, both wastewater- and case number-derived incidence exhibited a pronounced peak  
342 in mid-March. In Lausanne, the wastewater-derived incidence exhibited the highest number of infections  
343 from March 13-15, which matches the peak of infections determined by the SEIR model. If estimated  
344 based on confirmed cases, the highest number of new infections occurred from March 9-11. Considering  
345 the delay distributions from infection to case confirmation, this time range mainly reflects cases observed  
346 from March 17-24, coinciding with Swiss-wide positivity rates > 10% (Figure S1). The premature timing of


347 the peak may indicate that case numbers were truncated when testing capacity was exceeded and  
348 positivity rates were high.

349 In Lugano, wastewater-based incidence estimates yielded the highest infection numbers from March 10-  
350 12. This time frame partly overlapped with the SEIR-modelled infection peak, which occurred from March  
351 12-14. In contrast, the incidence peak determined from confirmed cases appeared later (March 17-19)  
352 and differed in shape compared to the other incidence estimates. This is another indication testing  
353 capacity during this period was insufficient to capture the full extent of the rise in cases during the height  
354 of the first wave.

355 In both locations, the decline in new infections was better captured by case number- than by wastewater-  
356 based incidence estimates. In Lausanne, the case number-based incidence exhibited a slow decay in new  
357 infections from mid-March to late April, similar to the reference incidence dynamics. In contrast, the decay  
358 in the wastewater-based incidence was faster. In Lugano the case number-derived incidence was also able  
359 to capture the tail end of the wave, whereas new infections based on wastewater data rapidly dropped  
360 to the baseline.

361 Finally, the wastewater-based incidence dynamics in both locations exhibited a second, smaller peak in  
362 April, which was driven by few high load measurements in each location. In Lausanne this feature also  
363 appeared in the corresponding case number-derived incidence dynamics and thus reflects a local spike in  
364 infections. In contrast, the origin of the second peak in Lugano is not evident. It may stem from one or  
365 more shedders that are not permanent inhabitants of the Lugano WWTP catchment and were therefore  
366 not included in the catchment-specific case numbers (e.g., commuters or external patients hospitalized  
367 within the catchment). The April peaks were not apparent in the SEIR model, which may be explained by  
368 differences in the type of input data used to determine incidence dynamics. Whereas wastewater loads

369 and case numbers were catchment-specific, the SEIR model was based on data for the entire canton. Local  
370 spikes in case numbers would thus appear attenuated in the reference incidence.



371  
372 *Figure 4. Comparison of COVID19 incidence dynamics estimated by the SEIR model, determined based on SARS-CoV-*  
373 *2 RNA loads in wastewater and based on confirmed case numbers. Incidence dynamics were determined by*  
374 *deconvolution of the wastewater loads and case numbers shown in Figure 3. The Zurich WWTP was not included in*  
375 *this analysis, because most wastewater samples yielded non-detectable SARS-CoV-2 RNA concentrations. A.U. =*  
376 *arbitrary units.*

#### 377 4. Conclusions

378 Our findings demonstrate that both confirmed case numbers and wastewater analysis are useful and  
379 independent metrics to estimate COVID-19 incidence dynamics. Wastewater outperformed case numbers  
380 with respect to the timing and shape of the peak incidence, whereas confirmed case numbers were a  
381 better indicator for incidence decline. In combination, the two metrics yielded complementary

382 information on incidence dynamics that correspond well to the reference dynamics determined by  
383 compartmental models.

384 It is important to consider that all three approaches rely on a number of assumptions, all of which are  
385 associated with a degree of uncertainty. For example, the SEIR model is based exclusively on data  
386 pertaining to severe COVID-19 cases (hospitalizations, deaths), and may thus miss events among age  
387 classes that have a low severity rate but normal virus shedding. Wastewater-derived incidence dynamics  
388 suffer from uncertainties in the accuracy of the SLD. And cases-number derived estimates rely on the  
389 delay distribution between infection and case confirmation, which may vary with time and location. While  
390 the sources of uncertainties of these assumptions are conceptually understood, they remain difficult to  
391 quantify due to the lack of reference data. It is therefore important and encouraging that despite these  
392 uncertainties, comparable incidence dynamics were obtained with three independent approaches.

393 Differences in the incidence dynamics determined by wastewater and confirmed cases may ultimately  
394 also be exploited to inform on the duration and degree of clinical undertesting. To do so, however, both  
395 incidence estimates need to be further advanced. In future work, wastewater-derived estimates can be  
396 enhanced by increasing the wastewater sampling frequency to smooth out measurement outliers,  
397 developing more sensitive assays to quantify the viral RNA at low concentrations, better determining  
398 SARS-CoV-2 RNA recovery from wastewater, and establishing a representative shedding load profile. Case  
399 number-derived incidence estimates can be improved by taking into account variations in the delay  
400 distributions from symptom onset to case confirmation. In Switzerland, the mean delay varied from 3 to  
401 8 days during the first wave <sup>47</sup>, yet herein it was held constant at 5.5 days.

402 Compared to the compartmental model, which relies on hospitalization and deaths, WBE can determine  
403 incidence dynamics with a faster turnaround time (RNA loads can be measured within 24 hours after  
404 sampling). Compared to clinical tests, an additional advantage of WBE is that a much lower number of

405 samples is required to determine incidence dynamics with reasonable accuracy. During high positivity rate  
406 regimes, WBE can thus yield information on the trajectory of a pandemic that is potentially more precise,  
407 more readily available and more economical than information from clinical data. We contend that WBE  
408 should be included by epidemiologists and public health agencies as a useful pandemic monitoring tool  
409 during periods with high test positivity rates.

#### 410 **Acknowledgements**

411 This work was supported by the Swiss National Science Foundation (project 31CA30\_196538), Eawag  
412 discretionary funds, and an EPFL COVID-19 grant. XFC was a fellow of the European Union's Horizon  
413 2020 research and innovation programme under the Marie Skłodowska–Curie Grant Agreement No.  
414 754462. We thank the operators of the Lugano, Lausanne and Zurich WWTPs for providing samples, the  
415 Swiss Federal Office of Public Health for catchment-specific case numbers, Jana Huisman for valuable  
416 input on SLDs, and Marie-Helene Corre, Elyse Stachler and Lea Caduff for lab assistance.

#### 417 **Appendix A: Supporting Information**

418 Supporting information to this article can be found online at <https://doi.org/xxx>.

419

## 420 References

- 421 (1) Sinclair, R. G.; Choi, C. Y.; Riley, M. R.; Gerba, C. P. Pathogen surveillance through monitoring of  
422 sewer systems. *Adv Appl Microbiol* 2008, *65*, 249–269.
- 423 (2) Fernandez-Cassi, X.; Timoneda, N.; Martínez-Puchol, S.; Rusiñol, M.; Rodriguez-Manzano, J.;  
424 Figuerola, N.; Bofill-Mas, S.; Abril, J. F.; Girones, R. Metagenomics for the study of viruses in urban  
425 sewage as a tool for public health surveillance. *Sci. Total Environ.* 2018, *618*, 870–880.
- 426 (3) Hovi, T.; Shulman, L. M.; van der Avoort, H.; Deshpande, J.; Roivainen, M.; DE Gourville, E. M. Role  
427 of environmental poliovirus surveillance in global polio eradication and beyond. *Epidemiol. Infect.*  
428 2012, *140*, 1–13.
- 429 (4) Kazama, S.; Miura, T.; Masago, Y.; Konta, Y.; Tohma, K.; Manaka, T.; Liu, X.; Nakayama, D.; Tanno,  
430 T.; Saito, M.; et al. Environmental surveillance of norovirus genogroups I and II for sensitive  
431 detection of epidemic variants. *Appl. Environ. Microbiol.* 2017, *83*.
- 432 (5) Bisseux, M.; Debroas, D.; Mirand, A.; Archimbaud, C.; Peigue-Lafeuille, H.; Bailly, J.-L.; Henquell, C.  
433 Monitoring of enterovirus diversity in wastewater by ultra-deep sequencing: An effective  
434 complementary tool for clinical enterovirus surveillance. *Water Res.* 2020, *169*, 115246.
- 435 (6) Wu, Y.; Guo, C.; Tang, L.; Hong, Z.; Zhou, J.; Dong, X.; Yin, H.; Xiao, Q.; Tang, Y.; Qu, X.; et al.  
436 Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol. Hepatol.*  
437 2020, *5*, 434–435.
- 438 (7) Medema, G.; Heijnen, L.; Elsinga, G.; Italiaander, R.; Brouwer, A. Presence of SARS-Coronavirus-2  
439 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the early stage of the  
440 epidemic in The Netherlands. *Environ. Sci. Technol. Lett.* 2020.
- 441 (8) Randazzo, W.; Truchado, P.; Cuevas-Ferrando, E.; Simón, P.; Allende, A.; Sánchez, G. SARS-CoV-2  
442 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area. *Water Res.* 2020,  
443 *181*, 115942.

- 444 (9) Ahmed, W.; Angel, N.; Edson, J.; Bibby, K.; Bivins, A.; O'Brien, J. W.; Choi, P. M.; Kitajima, M.;  
445 Simpson, S. L.; Li, J.; et al. First confirmed detection of SARS-CoV-2 in untreated wastewater in  
446 Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community. *Sci.*  
447 *Total Environ.* 2020, 728, 138764.
- 448 (10) Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-Massana, A.; Ko, A.  
449 I.; Malik, A. A.; Wang, D.; Wang, M.; et al. Measurement of SARS-CoV-2 RNA in wastewater tracks  
450 community infection dynamics. *Nat. Biotechnol.* 2020, 38, 1164–1167.
- 451 (11) Graham, K. E.; Loeb, S. K.; Wolfe, M. K.; Catoe, D.; Sinnott-Armstrong, N.; Kim, S.; Yamahara, K. M.;  
452 Sassoubre, L. M.; Mendoza Grijalva, L. M.; Roldan-Hernandez, L.; et al. SARS-CoV-2 RNA in  
453 wastewater settled solids is associated with COVID-19 cases in a large urban sewershed. *Environ.*  
454 *Sci. Technol.* 2021, 55, 488–498.
- 455 (12) Jahn, K.; Dreifuss, D.; Topolsky, I.; Kull, A.; Ganesanandamoorthy, P.; Fernandez-Cassi, X.; Bänziger,  
456 C.; Stachler, E.; Fuhrmann, L.; Jablonski, K. P.; et al. Detection of SARS-CoV-2 variants in Switzerland  
457 by genomic analysis of wastewater samples. *medRxiv* 2021.01.08.21249379; doi:  
458 <https://doi.org/10.1101/2021.01.08.21249379>.
- 459 (13) Crits-Christoph, A.; Kantor, R. S.; Olm, M. R.; Whitney, O. N.; Al-Shayeb, B.; Lou, Y. C.; Flamholz, A.;  
460 Kennedy, L. C.; Greenwald, H.; Hinkle, A.; et al. Genome sequencing of sewage detects regionally  
461 prevalent SARS-CoV-2 variants. *MBio* 2021, 12.
- 462 (14) The Cambridge Public Health Department (CPHD). Cambridge COVID-19 Data Center  
463 <https://cityofcambridge.shinyapps.io/COVID19/#shiny-tab-wastewater> (accessed Mar 1, 2021).
- 464 (15) Victoria State Government - Health and Human Services. Wastewater monitoring - coronavirus  
465 (COVID-19) <https://www.dhhs.vic.gov.au/wastewater-monitoring-covid-19> (accessed Mar 1,  
466 2021).

- 467 (16) Queensland Government. Wastewater surveillance program results  
468 [https://www.qld.gov.au/health/conditions/health-alerts/coronavirus-covid-19/current-](https://www.qld.gov.au/health/conditions/health-alerts/coronavirus-covid-19/current-status/wastewater)  
469 [status/wastewater](https://www.qld.gov.au/health/conditions/health-alerts/coronavirus-covid-19/current-status/wastewater) (accessed Mar 1, 2021).
- 470 (17) Rijksoverheid. Early indicators - Virus particles in wastewater  
471 <https://coronadashboard.government.nl/landelijk/rioolwater> (accessed Mar 1, 2021).
- 472 (18) World Health Organization. *Public health criteria to adjust public health and social measures in*  
473 *the context of COVID-19: annex to considerations in adjusting public health and social measures in*  
474 *the context of COVID-19, 12 May 2020.*; WHO/2019-  
475 nCoV/Adjusting\_PH\_measures/Criteria/2020.1; World Health Organization, 2020.
- 476 (19) Lemaitre, J. C.; Perez-Saez, J.; Azman, A. S.; Rinaldo, A.; Fellay, J. Assessing the impact of non-  
477 pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. *Swiss Med Wkly* 2020,  
478 150, w20295.
- 479 (20) Kitajima, M.; Iker, B. C.; Pepper, I. L.; Gerba, C. P. Relative abundance and treatment reduction of  
480 viruses during wastewater treatment processes--identification of potential viral indicators. *Sci.*  
481 *Total Environ.* 2014, 488-489, 290–296.
- 482 (21) Symonds, E. M.; Nguyen, K. H.; Harwood, V. J.; Breitbart, M. Pepper mild mottle virus: A plant  
483 pathogen with a greater purpose in (waste)water treatment development and public health  
484 management. *Water Res.* 2018, 144, 1–12.
- 485 (22) Leibowitz, J.; Kaufman, G.; Liu, P. Coronaviruses: propagation, quantification, storage, and  
486 construction of recombinant mouse hepatitis virus. *Curr Protoc Microbiol* 2011, *Chapter 15*, Unit  
487 15E.1.
- 488 (23) Lu, X.; Wang, L.; Sakthivel, S. K.; Whitaker, B.; Murray, J.; Kamili, S.; Lynch, B.; Malapati, L.; Burke,  
489 S. A.; Harcourt, J.; et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe  
490 Acute Respiratory Syndrome Coronavirus 2. *Emerging Infect. Dis.* 2020, 26.

- 491 (24) Besselsen, D. G.; Wagner, A. M.; Loganbill, J. K. Detection of rodent coronaviruses by use of  
492 fluorogenic reverse transcriptase-polymerase chain reaction analysis. *Comp Med* 2002, 52, 111–  
493 116.
- 494 (25) Haramoto, E.; Kitajima, M.; Kishida, N.; Konno, Y.; Katayama, H.; Asami, M.; Akiba, M. Occurrence  
495 of pepper mild mottle virus in drinking water sources in Japan. *Appl. Environ. Microbiol.* 2013, 79,  
496 7413–7418.
- 497 (26) Zhang, T.; Breitbart, M.; Lee, W. H.; Run, J.-Q.; Wei, C. L.; Soh, S. W. L.; Hibberd, M. L.; Liu, E. T.;  
498 Rohwer, F.; Ruan, Y. RNA viral community in human feces: prevalence of plant pathogenic viruses.  
499 *PLoS Biol.* 2006, 4, e3.
- 500 (27) Gendron, L.; Verreault, D.; Veillette, M.; Moineau, S.; Duchaine, C. Evaluation of filters for the  
501 sampling and quantification of RNA phage aerosols. *Aerosol Science and Technology* 2010, 44,  
502 893–901.
- 503 (28) Merkes, C. M.; Klymus K.E.; Allison M.J.; Goldberg C.; Helbing C.C.; Hunter M.E.; Jackson C.A.; Lance  
504 R.F.; Mangan A.M.; Monroe E.M.; Piaggio A.J.; Stokdyk J.P.; Wilson C.C.; Richter C. (2019) Generic  
505 qPCR Limit of Detection (LOD) / Limit of Quantification (LOQ) calculator. R Script. Available at:  
506 [https://github.com/cmerkes/qPCR\\_LOD\\_Calc](https://github.com/cmerkes/qPCR_LOD_Calc). DOI: <https://doi.org/10.5066/P9GT00GB>.
- 507 (29) Ståhlberg, A.; Kubista, M. The workflow of single-cell expression profiling using quantitative real-  
508 time PCR. *Expert Rev Mol Diagn* 2014, 14, 323–331.
- 509 (30) Benefield, A. E.; Skrip, L. A.; Clement, A.; Althouse, R. A.; Chang, S.; Althouse, B. M. SARS-CoV-2  
510 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of  
511 coronavirus viral load from 66 studies. *medRxiv* 2020.09.28.20202028; doi:  
512 <https://doi.org/10.1101/2020.09.28.20202028>.
- 513 (31) Linton, N. M.; Kobayashi, T.; Yang, Y.; Hayashi, K.; Akhmetzhanov, A. R.; Jung, S.-M.; Yuan, B.;  
514 Kinoshita, R.; Nishiura, H. Incubation Period and Other Epidemiological Characteristics of 2019

- 515 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case  
516 Data. *J Clin Med* 2020, *9*.
- 517 (32) Liu, P.; Cai, J.; Jia, R.; Xia, S.; Wang, X.; Cao, L.; Zeng, M.; Xu, J. Dynamic surveillance of SARS-CoV-  
518 2 shedding and neutralizing antibody in children with COVID-19. *Emerg. Microbes Infect.* 2020, *9*,  
519 1254–1258.
- 520 (33) Han, M. S.; Seong, M.-W.; Heo, E. Y.; Park, J. H.; Kim, N.; Shin, S.; Cho, S. I.; Park, S. S.; Choi, E. H.  
521 Sequential analysis of viral load in a neonate and her mother infected with severe acute  
522 respiratory syndrome coronavirus 2. *Clin. Infect. Dis.* 2020, *71*, 2236–2239.
- 523 (34) Bi, Q.; Wu, Y.; Mei, S.; Ye, C.; Zou, X.; Zhang, Z.; Liu, X.; Wei, L.; Truelove, S. A.; Zhang, T.; et al.  
524 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in  
525 Shenzhen, China: a retrospective cohort study. *Lancet Infect. Dis.* 2020, *20*, 911–919.
- 526 (35) R Core Team. R: A language and environment for statistical computing. *R foundation for statistical*  
527 *computing, Vienna, Austria* 2016. <https://www.R-project.org/>
- 528 (36) Fu, A.; Narasimhan, B.; Boyd, S. cvxr : an *r* package for disciplined convex optimization. *J Stat Softw*  
529 2020, *94*.
- 530 (37) Ruckdeschel, P.; Kohl, M. General Purpose Convolution Algorithm in S 4 Classes by Means of FFT. *J*  
531 *Stat Softw* 2014, *59*, 1–25.
- 532 (38) Gerrity, D.; Papp, K.; Stoker, M.; Sims, A.; Frehner, W. Early-pandemic wastewater surveillance of  
533 SARS-CoV-2 in Southern Nevada: Methodology, occurrence, and incidence/prevalence  
534 considerations. *Water Research X* 2021, *10*, 100086.
- 535 (39) Chik, A. H. S.; Glier, M. B.; Servos, M.; Mangat, C. S.; Pang, X.-L.; Qiu, Y.; D’Aoust, P. M.; Burnet, J.-  
536 B.; Delatolla, R.; Dorner, S.; et al. Comparison of approaches to quantify SARS-CoV-2 in wastewater  
537 using RT-qPCR: Results and implications from a collaborative inter-laboratory study in Canada. *J.*  
538 *Environ. Sci. (China)* 2021, *107*, 218–229.

- 539 (40) Pecson, B. M.; Darby, E.; Haas, C. N.; Amha, Y. M.; Bartolo, M.; Danielson, R.; Dearborn, Y.; Di  
540 Giovanni, G.; Ferguson, C.; Fevig, S.; et al. Reproducibility and sensitivity of 36 methods to quantify  
541 the SARS-CoV-2 genetic signal in raw wastewater: findings from an interlaboratory methods  
542 evaluation in the U.S. *Environ. Sci.: Water Res. Technol.* 2021.
- 543 (41) Ye, Y.; Ellenberg, R. M.; Graham, K. E.; Wigginton, K. R. Survivability, partitioning, and recovery of  
544 enveloped viruses in untreated municipal wastewater. *Environ. Sci. Technol.* 2016, *50*, 5077–5085.
- 545 (42) La Rosa, G.; Iaconelli, M.; Mancini, P.; Bonanno Ferraro, G.; Veneri, C.; Bonadonna, L.; Lucentini,  
546 L.; Suffredini, E. First detection of SARS-CoV-2 in untreated wastewaters in Italy. *Sci. Total Environ.*  
547 2020, *736*, 139652.
- 548 (43) Ahmed, W.; Tscharke, B.; Bertsch, P. M.; Bibby, K.; Bivins, A.; Choi, P.; Clarke, L.; Dwyer, J.; Edson,  
549 J.; Nguyen, T. M. H.; et al. SARS-CoV-2 RNA monitoring in wastewater as a potential early warning  
550 system for COVID-19 transmission in the community: A temporal case study. *Sci. Total Environ.*  
551 2021, *761*, 144216.
- 552 (44) D’Aoust, P. M.; Mercier, E.; Montpetit, D.; Jia, J.-J.; Alexandrov, I.; Neault, N.; Baig, A. T.; Mayne,  
553 J.; Zhang, X.; Alain, T.; et al. Quantitative analysis of SARS-CoV-2 RNA from wastewater solids in  
554 communities with low COVID-19 incidence and prevalence. *Water Res.* 2021, *188*, 116560.
- 555 (45) Gonzalez, R.; Curtis, K.; Bivins, A.; Bibby, K.; Weir, M. H.; Yetka, K.; Thompson, H.; Keeling, D.;  
556 Mitchell, J.; Gonzalez, D. COVID-19 surveillance in Southeastern Virginia using wastewater-based  
557 epidemiology. *Water Res.* 2020, *186*, 116296.
- 558 (46) Wu, F.; Zhang, J.; Xiao, A.; Gu, X.; Lee, W. L.; Armas, F.; Kauffman, K.; Hanage, W.; Matus, M.;  
559 Ghaeli, N.; et al. SARS-CoV-2 Titers in Wastewater Are Higher than Expected from Clinically  
560 Confirmed Cases. *mSystems* 2020, *5*.

561 (47) Huisman, J. S.; Scire, J.; Angst, D. C.; Neher, R. A.; Bonhoeffer, S.; Stadler, T. Estimation and  
562 worldwide monitoring of the effective reproductive number of SARS-CoV-2. *medRxiv*  
563 2020.11.26.20239368; doi: <https://doi.org/10.1101/2020.11.26.20239368>.

564